Basiliximab for prophylaxis of graft-versus-host disease in mismatched bone marrow transplantation
- VernacularTitle:巴利昔单克隆抗体预防HLA不相合骨髓移植中移植物抗宿主病
- Author:
Shuquan JI
;
Huiren CHEN
;
Hengxiang WANG
- Publication Type:Journal Article
- Keywords:
Antibodies, monoclonal;
Bone marrow transplantation;
Graft vs host disease
- From:
Chinese Journal of Organ Transplantation
2005;0(10):-
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the effects of Basiliximab on alloreactive T lymphocytes precursors, hematopoietic progenitor cells by ex vivo assay and prophylaxis of graft-versus-host disease (GVHD) in mismatched bone marrow transplantation.Methods Two groups were set up: (1) Basiliximab group including 72 leukemia patients subject to haploidentical bone marrow transplantation (BMT) with Basiliximab for prophylaxis of GVHD without ex vivo T-cell depletion. (2) Control group having 15 patients receiving the same regimen before Nov. 2000, without Basiliximab for GVHD prophylaxis. Limiting-dilution method was used to determine the effect of Basiliximab on reactivity of cytotoxic T lymphocyte precursors (CTLP). In the semi-solid hematopoietic culture system, the effect of Basiliximab on the colony proliferation of CFU-GM, BFU-E and CFU-Meg was measured. Results In Basiliximab group, 72 patients established trilineage with full donor hematopoietic reconstitution. Engraftment rate showed no statistical difference between the two groups. The incidence of grade Ⅱ-Ⅳ GVHD was 12.5 % (9 cases) in Basiliximab group and 33.3 % (5 cases) in control group respectively (P
